Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Cash & Equivalents (2016 - 2021)

Phio Pharmaceuticals' Cash & Equivalents history spans 10 years, with the latest figure at $26.5 million for Q3 2021.

  • For Q3 2021, Cash & Equivalents rose 56.81% year-over-year to $26.5 million; the TTM value through Sep 2021 reached $26.5 million, up 56.81%, while the annual FY2020 figure was $14.2 million, 103.95% up from the prior year.
  • Cash & Equivalents reached $26.5 million in Q3 2021 per PHIO's latest filing, down from $29.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $32.7 million in Q1 2021 to a low of $2.7 million in Q1 2018.
  • Average Cash & Equivalents over 5 years is $12.9 million, with a median of $10.9 million recorded in 2019.
  • Peak YoY movement for Cash & Equivalents: plummeted 73.97% in 2018, then skyrocketed 381.78% in 2019.
  • A 5-year view of Cash & Equivalents shows it stood at $3.6 million in 2017, then soared by 311.15% to $14.9 million in 2018, then crashed by 53.22% to $7.0 million in 2019, then soared by 103.95% to $14.2 million in 2020, then skyrocketed by 86.25% to $26.5 million in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Cash & Equivalents are $26.5 million (Q3 2021), $29.4 million (Q2 2021), and $32.7 million (Q1 2021).